Gilead Sciences (GILD) R&D In Process (2019 - 2026)

Gilead Sciences has reported R&D In Process for 8 years, with the latest figure at $107.0 million in Q1 2026.

• For the quarter ending Q1 2026, R&D In Process fell 57.71% year-over-year to $107.0 million; the trailing twelve-month figure through Mar 2026 stood at $418.0 million (down 46.75% YoY), and the FY2025 full-year result was $1.0 billion, down 78.04% from the prior year.
• R&D In Process for Q1 2026 stood at $107.0 million, up from $80.0 million in the prior quarter.
• The five-year high for R&D In Process was $3.9 billion in Q1 2024, with the low at -$11.0 million in Q4 2024.
• Historically, R&D In Process has averaged $389.5 million across 5 years, with a median of $158.0 million in 2022.
• Annual changes were most pronounced in 2023 — R&D In Process soared 2550.0% — and 2024, when it slumped 110.89%.
• Gilead Sciences' R&D In Process stood at $158.0 million in 2022, then sank by 36.08% to $101.0 million in 2023, then tumbled by 110.89% to -$11.0 million in 2024, then jumped by 827.27% to $80.0 million in 2025, then soared by 33.75% to $107.0 million in 2026.
• The last three R&D In Process figures came in at $107.0 million (Q1 2026), $80.0 million (Q4 2025), and $170.0 million (Q3 2025), per Business Quant data.